ShanX Medtech Secures €24 M To Bring Ultra-Rapid Antimicrobial Susceptibility Diagnostics To Market

The oversubscribed round included a mix of equity, grants, and the Innovatiekrediet, with equity led by Borski Fund, NextGen Ventures, CbusineZ, Brabantse Ontwikkelings Maatschappij (BOM), Invest-NL and a strategic angel fund.

Additionally, ShanX was awarded an €8.85 million European Commission contract (HADEA/2025/CPN/0006), developed by the Health Emergency Preparedness and Response Authority (DG HERA) in collaboration with the European Health and Digital Executive Agency (HADEA). This brings ShanX’s total financing to €24 million.

Read Also - London-Based Biographica Secures £7M To Expand AI Crop Design Globally

Dr Sophia E. Shanko, founder and CEO of ShanX Medtech, said, “We founded ShanX Medtech because of a single patient story, one that revealed how much is at stake when diagnostic results arrive too late.

“Our vision is to equip every clinician with the ability to act decisively, guided by diagnostic evidence in real-time. This funding brings us significantly closer to delivering ultra-rapid AST directly to both laboratory and point-of-care environments; faster, simpler, and more accessible than ever before.”

Founded in 2019 and based at Eindhoven’s High Tech Campus, ShanX Medtech (SXM) develops in-vitro diagnostic (IVD) solutions for rapid antimicrobial susceptibility testing (AST) directly from patient samples.

Using novel chemistry to monitor microbial metabolism, SXM delivers results in under an hour with minimal user involvement significantly faster than traditional methods requiring trained staff and longer processing times. Its proprietary FLORA™ chemical composition enables real-time pathogen metabolism monitoring.

The newly raised capital will help ShanX accelerate final development, clinical validation, regulatory approval, and the commercial launch of its diagnostic platform.

Simone Brummelhuis, Partner at Borski Fund, said, “Following an extensive market analysis of innovations addressing antimicrobial resistance, ShanX’s technology clearly emerged as best-in-class. While the company’s initial go-to-market strategy focuses on a well-defined women’s health application in urinary tract infections the underlying platform offers substantial potential across a wide range of clinical indications.

“We are proud to support Sophia and her exceptional team in realising their ambitious vision. The oversubscribed financing round, together with multiple multi-million-euro commercial contracts, underscores both the strength of the technology and the founder’s proven commercial execution.”